Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of crizotinib in ALK fusion variants.

Literature DB >> 27867635

Efficacy of crizotinib in ALK fusion variants.

Tetsu Kobayashi¹, Hajime Fujimoto¹, Esteban C Gabazza².

Abstract

Entities: Chemical Gene

Year: 2016 PMID： 27867635 PMCID： PMC5107530 DOI： 10.21037/jtd.2016.10.62

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

17 in total

1. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors: Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal: Sci Transl Med Date: 2012-01-25 Impact factor: 17.956

2. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors: Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal: N Engl J Med Date: 2010-10-28 Impact factor: 91.245

3. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.

Authors: Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe
Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544

4. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.

Authors: Sabina Antonela Antoniu
Journal: Expert Opin Ther Targets Date: 2011-01-05 Impact factor: 6.902

5. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Authors: Takaaki Sasaki; Jussi Koivunen; Atsuko Ogino; Masahiko Yanagita; Sarah Nikiforow; Wei Zheng; Christopher Lathan; J Paul Marcoux; Jinyan Du; Katsuhiro Okuda; Marzia Capelletti; Takeshi Shimamura; Dalia Ercan; Magda Stumpfova; Yun Xiao; Stanislawa Weremowicz; Mohit Butaney; Stephanie Heon; Keith Wilner; James G Christensen; Michel J Eck; Kwok-Kin Wong; Neal Lindeman; Nathanael S Gray; Scott J Rodig; Pasi A Jänne
Journal: Cancer Res Date: 2011-07-26 Impact factor: 12.701

Review 6. The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors: Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal: Eur J Cancer Date: 2010-04-24 Impact factor: 9.162

7. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Authors: Johannes M Heuckmann; Hyatt Balke-Want; Florian Malchers; Martin Peifer; Martin L Sos; Mirjam Koker; Lydia Meder; Christine M Lovly; Lukas C Heukamp; William Pao; Ralf Küppers; Roman K Thomas
Journal: Clin Cancer Res Date: 2012-08-21 Impact factor: 12.531

8. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Authors: Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer Rizvi; Ennapadam S Venkatraman; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller
Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531

9. A mouse model for EML4-ALK-positive lung cancer.

Authors: Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal: Proc Natl Acad Sci U S A Date: 2008-12-08 Impact factor: 11.205

10. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors: D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316

6 in total

1. Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors: Tetsu Kobayashi; Hajime Fujimoto; Corina D'Alessandro-Gabazza; Esteban C Gabazza; Osamu Hataji
Journal: J Thorac Dis Date: 2017-09 Impact factor: 2.895

Review 2. MET targeting: time for a rematch.

Authors: Jonas P Koch; Daniel M Aebersold; Yitzhak Zimmer; Michaela Medová
Journal: Oncogene Date: 2020-02-07 Impact factor: 8.756

3. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.

Authors: Wang Zhiwei; Jiang Yuan; Yao Yihui; Hou Xin; Chen Jingtao; Shi Lei; Duan Yongjian
Journal: Thorac Cancer Date: 2017-07-25 Impact factor: 3.500